Readers' commentANCHOR Trial Conclusions Regarding the Effects of Pure Eicosapentaenoic Acid on Low-Density Lipoprotein Cholesterol
References (8)
- et al.
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
Am J Cardiol
(2012) - et al.
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from MARINE trial)
Am J Cardiol
(2011) - et al.
Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study
Am J Clin Nutr
(2007) - et al.
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
Clin Ther
(2007)
There are more references available in the full text version of this article.
Cited by (5)
The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
2021, European Journal of Preventive CardiologySpotlight on icosapent ethyl for cardiovascular risk reduction: Evidence to date
2020, Vascular Health and Risk ManagementOmega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials
2019, Current Atherosclerosis ReportsN-3 fatty acids: Role in treating dyslipidemias and preventing cardiovascular disease
2015, Contemporary EndocrinologyN-3 fatty acids: Role in treating dyslipidemias and preventing cardiovascular disease
2015, Dyslipidemias: Pathophysiology, Evaluation and Management
Copyright © 2013 Elsevier Inc. All rights reserved.